Physician profile
Bruce M Decter
NPI 1114905437
$88,887.62
in general payments reported to CMS, 2019-2025
62 companies · $19K in 2025
The $19K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $15K · 2021: $5,604 · 2022: $5,190 · 2023: $4,922 · 2024: $6,282 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $8,102 · Consulting Fee: $4,950 · Travel and Lodging: $866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,239.84 |
| Food and Beverage | $8,102.37 |
| Consulting Fee | $4,950.00 |
| Travel and Lodging | $865.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $35,503.44 | 2019-2025 | |
| Amarin Pharma, INC. | $25,568.29 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $6,685.07 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $4,490.36 | 2019-2025 | Evkeeza |
| Astrazeneca Pharmaceuticals Lp | $1,697.94 | 2019-2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $1,663.87 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,511.97 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,412.15 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,257.90 | 2019-2024 | Jardiance |
| Abbott Laboratories | $1,171.63 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Aveir |
| Merck Sharp & Dohme LLC | $868.34 | 2019-2025 | Verquvo, Capvaxive |
| Amgen INC. | $786.60 | 2019-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $716.25 | 2020-2025 | Sapien 3 Ultra Resilia |
| Alnylam Pharmaceuticals INC. | $667.06 | 2020-2025 | Amvuttra |
| Kowa Pharmaceuticals America, INC. | $411.03 | 2019-2024 | Livalo |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Decter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.